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34 Children with a late diagnosis of CF despite a long-established
newborn screening programme
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Respiratory, Auckland, New Zealand
Objectives: Neonatal screening for CF has been continuous in New Zealand (NZ)
for 30 years. Initially this was by two blood immunoreactive trypsin (IRT) levels
until 1996 when a three gene detection replaced the second IRT measurement.
Aim: To determine the number of children with a late diagnosis and why they were
not detected despite our long term newborn screening programme.
Methods: Retrospective review of all children with CF under full care at Starship
Children’s Hospital, Auckland, NZ from 2003–2012 which includes patients up to
18 years of age to therefore determine missed on screening from 1985–2012 in the
greater Auckland region with a general population of 800,000 to 1.2 million over
this time.
Results: In the last decade 100 children with CF were in this clinic of whom 18
had a late diagnosis, mean age 14 months (range 6 weeks to 11 years). Eight of
them were born overseas in regions without a newborn screening programme at
that time. Ten were born in NZ; 4 were pancreatic sufﬁcient and 6 were pancreatic
insufﬁcient. Nine were missed as the IRT level was not in the highest 1% and
therefore the gene determination was not undertaken, or they had “uncommon”
gene, undetectable on screening. One child’s parents refused newborn screening.
All ten had recurrent pneumonias, 2 had established bronchiectasis, 4 FTT and 1
had severe liver disease leading to the diagnosis.
Conclusion: Even with an established newborn screening programme in place,
cystic ﬁbrosis should be considered in the appropriate clinical setting.
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Neonatal Screening for Cystic Fibrosis (NS CF) has been introduced in the Czech
Republic (CR) since October 2009. For the Moravia region, CF Center of University
Hospital Brno performs examinations (IRT/DNA analysis and comprehensive care
for patients with 1 and/or 2 mutations in the CFTR gene). Every year we examine
IRT level from dry blood spot in around 40,000 newborns, a positive result and DNA
analysis of 50 CFTR mutations (Elucigene) is indicated in about 1% of newborns
and in about 1% of the analyzes we conﬁrm the newborn with CF.
As part of comprehensive care for families of newborns with one and/or two
mutations in the CFTR gene, we noted certain facts, that we further analyzed:
– Lower prevalence of CF in the study population compared to the statistics.
– New spectrum of CFTR mutations in the Moravia population.
– Detection of CF at an older still untreated siblings.
– A false negative IRT result.
– Non-cooperation of the family.
– Incorrect reset of DNA analysis due to contamination of blood spot.
– Detection of a part of healthy heterozygotes in the population.
– Psychological stress of parents.
– Adoption as a result of diagnosis CF in the newborn.
Conclusions: NS CF in CR deﬁnitely met expectations and leads to early detection
of CF patients. NS CF but also brings some unexpected ﬁndings and situations
to be applied within the comprehensive care and genetic counseling. Detection of
patients with CF with NS is not 100%. Detection of heterozygotes is irrelevant −
unsolicited ﬁnding that brings stress situations, but also allows the family genetic
counseling and targeted CF prevention. Efforts to minimize the psychological stress
of parents will never be completely successful.
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Objectives: To assess the diagnostic and clinical outcomes of infants in their ﬁrst
year of life, followed up after cystic ﬁbrosis newborn screening (NS).
Methods: A transversal and descriptive study including 24 infants followed up
from 2010–2012 that were screened by immunoreactive trypsinogen (IRT) tests
in 2 measurements in the ﬁrst month of age with the cut-off value 70 ng/ml
and positive sweat chloride test (SCT). The clinical outcomes were assessed in
the months 0, 3, 6, 9, 12. All received similar treatment. Among 24 infants:
16 were male and 21 Caucasian. 3 died. IRT was realized during the ﬁrst week
and in the 3rd or 4rt week of life. The mean values were: IRT1 = 191 ng/ml
and IRT2=207 ng/ml. The mean values of SCT were100.3 and 110mEq/l. 90%
presented respiratory manifestations and 33.33% had pulmonary colonization by
P. aeruginosa. All 24 patients had digestive manifestations with 21% of steatocrit
mean values. In the ﬁrst month of life, 16.66% and 12.5% of them had already
been hospitalized for respiratory disorders and meconium ileus respectively. The
most critical clinical health condition happened between 3 and 6 months of life, in
which 45.83% were hospitalized (20.83% and 25% with metabolic and respiratory
disorders). In the evaluation of 0, 3 and 6 months of life all infants presented one or
more of: diarrhea, malnutrition, weight percentile <3, persistent cough, dehydration
and pulmonary exacerbations. No patient had the characteristics mentioned above
at the age of 9 and 12 months.
Conclusion: The NS contributed for a good nutritional status, improvement of
metabolic and respiratory conditions and lack of hospitalizations after 6 months of
age.
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Background: Newborn screening for CF, based on an IRT-DNA-IRT protocol, was
introduced in Switzerland in January 2011. In the 2-years pilot phase, we compared
the performance of two sweat test methods for diagnosing CF.
Methods: All children with a positive screening result were referred to a CF center
for a sweat test with:
a. Macroduct (measuring chloride; at least 15ml sweat required); and
b. Nanoduct (conductivity; at least 3ml sweat required).
If sweat test results were positive, borderline or inconclusive, an extensive DNA
analysis was performed.
Results: Within two years, 162 children were screened positive and further inves-
tigations in a CF center were needed. In 49 the diagnosis CF could be conﬁrmed,
and in 12 an equivocal CF was made; 88 children had negative investigations, and
13 children were not yet fully investigated. At the time of writing the abstract,
details of the investigations were only available for 141 children. They were seen
in a CF center at a median age of 25 days. Macroduct was attempted in 121
(86%), Nanoduct in 136 (96%). A reliable result was available in 74% (89/121) for
Macroduct and 86% (117/136) for Nanoduct. In 81 children both sweat tests could
be performed, while in 36 only Nanoduct and in 8 only Macroduct was feasible.
In 16 (9.8%) children none of the two sweat tests could be performed at the ﬁrst
assessment. Sensitivity and speciﬁcity data will be presented at the conference when
all investigation details will be available.
Conclusions: In this pilot study, Nanoduct showed a better feasibility for use
in newborns compared to the Macroduct, mainly because it needs a lower sweat
volume.
